Q-linea receives contract for second US ASTar instrument
Q-linea AB (publ) (OMX: QLINEA) today announces the signing of the second US commercial contract for ASTar® instrumentation.
Installation and training will take place by the end of Q1 2025 in a multi-hospital system.
Stuart Gander, President & CEO of Q-linea, stated, “We are excited by our ongoing commercial progress and look forward to demonstrating improved clinical outcomes for patients with bacteremia within this healthcare system.”